Results
|
|
1.
|
Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure. MedStar authors:
- Amin, Shril M
- Chilipko, Allison A
- Macharia, David
- Norwood, Daryn K
- Still, Kimberly L
Year: 2013
Citation: - Consultant Pharmacist. 28(9):579-83, 2013 Sep.
Institution: - MedStar Union Memorial Hospital
Medline publication type:
All authors: - Amin SM, Chilipko AA, Macharia D, Norwood DK, Still KL
|
|
|
2.
|
Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. MedStar authors:
- Chen, Fang
- Lipinski, Michael J
- Pendyala, Lakshmana K
- Torguson, Rebecca
- Waksman, Ron
Citation: - Atherosclerosis. 235(2):295-8, 2014 Aug.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Observational Study
All authors: - Chen F, Lipinski MJ, Pendyala LK, Torguson R, Waksman R
|
|
|
3.
|
|
|
|
4.
|
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
Year: 2017
Citation: - The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
|
|
|
5.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
|
6.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
7.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
|
8.
|
Gestational diabetes: implications for cardiovascular health. [Review] MedStar authors:
- Ratner, Robert E
- Sullivan, Shannon D
- Umans, Jason G
Year: 2012
Citation: - Current Diabetes Reports. 12(1):43-52, 2012 Feb.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Medline publication type:
All authors: - Ratner R, Sullivan SD, Umans JG
|
